Dyne Therapeutics Competitors and Similar CompaniesClear all
Dyne Therapeutics's competitors and similar companies include Neurogene, Ocugen, Precigen and Asklepios BioPharmaceutical.
 Dyne Therapeutics Dyne Therapeutics is a biotechnology company which is engaged in the development of targeted therapies for patients with serious muscle diseases. |  Neurogene Neurogene is a biotechnology company which accelerates the development of genetic medicines to people with devastating neurological diseases. |  Ocugen Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to treat eye diseases |  Precigen Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases. |  Asklepios BioPharmaceutical Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein. | |
Founding Date | Founding Date 2018 | Founding Date 2018 | Founding Date 2013 | Founding Date 1998 | Founding Date 2001 |
Type | Type Public | Type Private | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Waltham, US HQ | Locations New York, US HQ Houston, US | Locations Malvern, US HQ | Locations Germantown, US HQ Gent, BE Sioux Center, US | Locations Chapel Hill, US HQ Roslin, GB |
Employees | Employees 1451% decrease | Employees 1091% decrease | Employees 84425% increase | Employees 601 | Employees 5172% increase |
Valuation ($) | Valuation ($) 3.1 b | Valuation ($) N/A | Valuation ($) 292.1 m | Valuation ($) 246.6 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $4.4m (FY, 2025) | Revenue (est.) $9.7m (FY, 2025) | Revenue (est.) N/A |
Net income | Net income ($446.2m) (FY, 2025) | Net income N/A | Net income ($67.8m) (FY, 2025) | Net income ($250.6m) (FY, 2025) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 68.5m (over 7 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 235m (about 7 years ago) |
Total funding raised | Total funding raised $ 165m | Total funding raised $ 68.5m | Total funding raised N/A | Total funding raised $ 379m | Total funding raised $ 235m |
For sources of this data, please see the company profile
View Company Profiles
Neurogene
HQ
New York, US
Employees
109↓ 1% decrease
Neurogene is a biotechnology company which accelerates the development of genetic medicines to people with devastating neurological diseases.
View companyOcugen
HQ
Malvern, US
Employees
84
Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to treat eye diseases
View companyPrecigen
HQ
Germantown, US
Employees
601
Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases.
View companyAsklepios BioPharmaceutical
HQ
Chapel Hill, US
Employees
517↑ 2% increase
Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein.
View company